Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Indian share markets remain firm
Thu, 22 Jan 01:30 pm

Indian share markets continued to remain firm in the post-noon trading session. Majority of the sectoral indices are trading in the green led by pharma & auto stocks. Oil & gas and consumer durable are among the few stocks trading in the red today.

BSE-Sensex is up 88 points and NSE-Nifty is trading 15 points up. BSE Mid Cap is trading 0.1% up and BSE Small Cap index is trading up by 0.4%. The rupee is trading at 61.66 to the US dollar.

Majority of the food stocks are trading firm led by United Spirits and Agro Tech Foods. As per a leading financial daily, Britannia wants to increase the proportion of in-house manufacturing of products from the present level of 50% to 60%. For this the company plans to invest Rs 4 bn over the next 18 months in 12 new lines across the country. The company presently has 35 contract manufacturers across the country and this is getting difficult for it to control. The company does not intend to go for 100% in-house manufacturing as it will result in higher freight costs. Apart from Tamil Nadu and Gujarat plants, the company will open three new lines at its upcoming Bengaluru plant in Bidadi. Another new line is likely to come up at its Odisha plant. Britannia stock is presently trading down 0.5%.

Most of the foreign pharma stocks are trading in the green with Novartis and Pfizer being the biggest gainers. As per a leading financial daily, the US Food and Drug Administration (USFDA) has given approval for Novartis AG's injectable drug, Cosentyx. The drug is used for the treatment of moderate to severe form of skin disease called plaque psoriasis. Novartis' drug will face competition from rival IL-17 inhibitors when Eli Lily & Co begins marketing its IL-17 inhibitor drug ixekizumab in the first half of 2015. Novartis stock is presently trading up 2.1%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Equitymaster requests your view! Post a comment on "Indian share markets remain firm". Click here!


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Jan 19, 2018 (Close)